Bull’s-eye pattern of pancreatic-duct stones on multidetector computed tomography and gene-mutation-associated pancreatitis (GMAP)

Graziani, Rossella; Frulloni, Luca; Cicero, Calogero Edoardo; Manfredi, Riccardo; Ambrosetti, Maria Chiara; Mautone, S.; Mucelli, Roberto Pozzi

doi:10.1007/s11547-012-0888-4

Cited by 10 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Electrochemotherapy is definitely a promising technique for cancer treatment [16,22,24] but how to assess treated tumor response is still the problem [52][53][54][55][56][57][58][59][60][61][62][63][64]. In fact, as highlighted in our preliminary experience, the RECIST 1.1, using the variation of largest diameter both on CT and MR images, did not provide an appropriate patient stratification in responders or non-responders after ECT [22].…”

Section: Discussionmentioning

confidence: 99%

Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy

Izzo

Granata

Fusco

et al. 2021

JCM

View full text Add to dashboard Cite

Objective. To assess local disease control rates (LDCR) and overall survival (OS) in locally advanced pancreatic cancer (LAPC) treated with electrochemotherapy (ECT). Methods. Electrochemotherapy with bleomycin was performed in 25 LAPC patients who underwent baseline Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT) and Position Emission Tomography (PET) scans before ECT and 1 and 6 months post ECT. LDCR were assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Choi criteria. Needle electrodes with fixed linear (N-30-4B) or fixed hexagonal configurations (N-30-HG or I-40-HG or H-30-ST) or variable geometry (VGD1230 or VGD1240) (IGEA S.p.A., Carpi, Italy) were used to apply electric pulses. Pain evaluation was performed pre-ECT, after 1 month and after 6 months with ECT. Overall survival estimates were calculated by means of a Kaplan-Meier analysis. Results. At 1 month after ECT, 76% of patients were in partial response (PR) and 20% in stable disease (SD). Six months after ECT, 44.0% patients were still in PR and 12.0% in SD. A LDCR of 56.0% was reached six months after ECT: 13 patients treated with fixed geometry had a LDCR of 46.1%, while for the 12 patients treated with variable geometry, the LDCR was 66.7%. The overall survival median value was 11.5 months: for patients treated with fixed geometry the OS was 6 months, while for patients treated with variable geometry it was 12 months. Electrochemotherapy was well-tolerated and abdominal pain was rapidly resolved. Conclusions. Electrochemotherapy obtained good results in terms of LDCR and OS in LAPC. Multiple needle insertion in a variable geometry configuration optimized by pre-treatment planning determined an increase in LDCR and OS compared to a fixed geometry configuration.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy

Izzo

Granata

Fusco

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Presence of pancreatic calcifications (CT), dilation of main pancreatic duct > 6 mm (CT, MR), dilation of secondary ducts (MRCP), and pancreatic atrophy (CT, MR) were therefore recorded. A bone window was evaluated, when possible, to identify the presence of a "bull's eye" appearance [19] .…”

Section: Methodsmentioning

confidence: 99%

Painless chronic pancreatitis

Amodio¹,

Marchi²,

Pretis³

et al. 2020

Digestive and Liver Disease

View full text Add to dashboard Cite

“…Unenhanced CT may be considered complementary to MRI and MRCP because it allows to easily identify and precisely localize both pancreatic parenchymal and ductal calcifications (important information for treatment planning) (Figure 19), and permits to study the structure of stones, in order to identify features suggestive of gene mutations associated with CP. In particular stones with a hypodense central core, with the so-called "bull's eye" appearance, are detected in 67% of patients with a gene mutation associated CP [53] and identifying these patients is important because they have an even higher risk of developing PDAC and thus require strict surveillance, genetic counseling and family testing.…”

Section: Ct Imagingmentioning

confidence: 99%

Imaging of Pancreatitis

Morana¹,

Beleù²,

Nistri³

et al. 2023

Multidisciplinary Management of Acute and Chronic Pancreatitis

View full text Add to dashboard Cite

Imaging of pancreatitis is very complicated. Correct detection of the various forms of pancreatitis is essential for adequate early therapy. In acute pancreatitis, imaging is useful for diagnosis, but above all for the research of causes and any complications. In autoimmune forms, imaging raises clinical suspicion and guides the response to therapy and the search for associated pathologies. In chronic pancreatitis, imaging is essential for grading, differential diagnosis with neoplastic diseases and follow-up. The classical CT and MRI methods play a fundamental role in this sense, being increasingly supported by modern special techniques such as S-MRCP and T1-mapping. Finally, interventional radiology today represents one of the main minimally invasive methods for the diagnosis and treatment of complications.

show abstract

Bull’s-eye pattern of pancreatic-duct stones on multidetector computed tomography and gene-mutation-associated pancreatitis (GMAP)

Abstract: The presence of duct stones with a bull's-eye pattern correlates with GMAP. Duct stones with diameter ≥15 mm are another sign suggestive of GMAP.

Cited by 10 publications

References 27 publications

Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy

Clinical Phase I/II Study: Local Disease Control and Survival in Locally Advanced Pancreatic Cancer Treated with Electrochemotherapy

Painless chronic pancreatitis

Imaging of Pancreatitis

Contact Info

Product

Resources

About